achieve life sciences - ACHV

ACHV

Close Chg Chg %
3.07 0.02 0.65%

Open Market

3.09

+0.02 (0.65%)

Volume: 379.92K

Last Updated:

Jan 17, 2025, 4:00 PM EDT

Company Overview: achieve life sciences - ACHV

ACHV Key Data

Open

$3.09

Day Range

3.02 - 3.14

52 Week Range

3.02 - 5.59

Market Cap

$105.58M

Shares Outstanding

34.39M

Public Float

27.60M

Beta

1.67

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.13

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

277.43K

 

ACHV Performance

1 Week
 
0.00%
 
1 Month
 
-16.26%
 
3 Months
 
-39.17%
 
1 Year
 
-31.64%
 
5 Years
 
-75.78%
 

ACHV Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8
Full Ratings ➔

About achieve life sciences - ACHV

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

ACHV At a Glance

Achieve Life Sciences, Inc.
1040 West Georgia Street
Vancouver, British Columbia V6E 4H1
Phone 1-604-210-2217 Revenue 0.00
Industry Pharmaceuticals: Major Net Income -29,815,000.00
Sector Health Technology Employees 22
Fiscal Year-end 12 / 2024
View SEC Filings

ACHV Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -3.067
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.202

ACHV Efficiency

Revenue/Employee N/A
Income Per Employee -1,355,227.273
Receivables Turnover N/A
Total Asset Turnover N/A

ACHV Liquidity

Current Ratio 0.816
Quick Ratio 0.816
Cash Ratio 0.747

ACHV Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -120.85
Return on Equity -869.876
Return on Total Capital -195.086
Return on Invested Capital -860.462

ACHV Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 109.475
Total Debt to Total Assets 86.371
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 0.039
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Achieve Life Sciences - ACHV

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
255.00K 250.00K 236.00K 228.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
255.00K 250.00K 236.00K 228.00K
Depreciation
32.00K 27.00K 36.00K 28.00K
Amortization of Intangibles
223.00K 223.00K 200.00K 200.00K
COGS Growth
+0.39% -1.96% -5.60% -3.39%
Gross Income
(255.00K) (250.00K) (236.00K) (228.00K)
Gross Income Growth
-0.39% +1.96% +5.60% +3.39%
Gross Profit Margin
- - - -
-
2020 2021 2022 2023 5-year trend
SG&A Expense
14.49M 32.84M 40.56M 27.02M
Research & Development
6.88M 23.97M 30.08M 15.81M
Other SG&A
7.61M 8.88M 10.49M 11.21M
SGA Growth
-10.93% +126.59% +23.51% -33.38%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 528.00K
-
EBIT after Unusual Expense
(14.75M) (33.09M) (40.80M) (27.78M)
Non Operating Income/Expense
20.00K (58.00K) 239.00K 816.00K
Non-Operating Interest Income
69.00K 17.00K 199.00K 825.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 1.79M 2.85M
-
Interest Expense Growth
- - - +59.47%
-
Gross Interest Expense
- - 1.79M 2.85M
-
Interest Capitalized
- - - -
-
Pretax Income
(14.73M) (33.15M) (42.35M) (29.82M)
Pretax Income Growth
+10.16% -125.06% -27.74% +29.60%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(14.73M) (33.15M) (42.35M) (29.82M)
Minority Interest Expense
- - - -
-
Net Income
(14.73M) (33.15M) (42.35M) (29.82M)
Net Income Growth
+10.16% -125.06% -27.74% +29.60%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(14.73M) (33.15M) (42.35M) (29.82M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(14.73M) (33.15M) (42.35M) (29.82M)
EPS (Basic)
-5.4176 -4.0828 -3.9979 -1.5037
EPS (Basic) Growth
+86.38% +24.64% +2.08% +62.39%
Basic Shares Outstanding
2.72M 8.12M 10.59M 19.83M
EPS (Diluted)
-5.4176 -4.0828 -3.9979 -1.5037
EPS (Diluted) Growth
+86.38% +24.64% +2.08% +62.39%
Diluted Shares Outstanding
2.72M 8.12M 10.59M 19.83M
EBITDA
(14.49M) (32.84M) (40.56M) (27.02M)
EBITDA Growth
+10.93% -126.59% -23.51% +33.38%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 16.00
Number of Ratings 8 Current Quarters Estimate -0.355
FY Report Date 03 / 2025 Current Year's Estimate -1.144
Last Quarter’s Earnings -0.36 Median PE on CY Estimate N/A
Year Ago Earnings -1.221 Next Fiscal Year Estimate -0.608
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 8 5
Mean Estimate -0.36 -0.30 -1.14 -0.61
High Estimates -0.31 -0.23 -0.86 0.08
Low Estimate -0.42 -0.36 -1.41 -1.04
Coefficient of Variance -14.27 -18.08 -17.41 -84.28

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 7
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Achieve Life Sciences - ACHV

Date Name Shares Transaction Value
Apr 24, 2024 Cindy A. Jacobs President & CMO; Director 34,511 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 24, 2024 Cindy A. Jacobs President & CMO; Director 30,554 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.51 per share 137,798.54
Apr 24, 2024 Cindy A. Jacobs President & CMO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 24, 2024 John A. Bencich CEO; Director 101,724 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 24, 2024 John A. Bencich CEO; Director 95,636 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.51 per share 431,318.36
Apr 24, 2024 John A. Bencich CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 24, 2024 Richard Alistair Balfour Stewart Executive Chairman; Director 61,001 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 24, 2024 Richard Alistair Balfour Stewart Executive Chairman; Director 50,876 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.51 per share 229,450.76
Apr 24, 2024 Richard Alistair Balfour Stewart Executive Chairman; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 24, 2024 Jerry Wan Principal Accounting Officer 12,057 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 24, 2024 Jerry Wan Principal Accounting Officer 9,807 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.51 per share 44,229.57
Apr 24, 2024 Jerry Wan Principal Accounting Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 30, 2024 Bridget A. Martell Director 31,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Achieve Life Sciences in the News